Can falsified or substandard antimicrobials increase antimicrobial resistance?

Lilly’s Omvoh is an IL23p19-targeting monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. Image

Share this article Approval from the MHLW makes Vyloy the first and only CLDN18.2-targeted therapy approved in the world, according to Astellas’ 26 March press

A dozen U.S. Senators and three witnesses sharply criticized Medicare Advantage (MA) marketing schemes during a Senate Finance Committee hearing yesterday. Participants blasted the “unscrupulous,”